# Integral Consulting (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/integral-consulting-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 60 |
| Citations | 21,961 |
| City | Seattle |
| Country | US |
| Description | Integral Consulting (United States) is a research organisation in Seattle, US. OpenAlex records 2,774 works and 21,961 citations for it. 1,192 researchers list it as their most recent affiliation. |
| Homepage | https://www.integral-corp.com/ |
| OpenAlex ID | https://openalex.org/I4210163578 |
| Region | Washington |
| Researchers | 1,192 |
| ROR ID | https://ror.org/05hv0ec94 |
| Type | company |
| Works | 2,774 |

## University papers

Showing 12 of 31.

- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial](https://scholariq.org/papers/long-term-management-of-moderate-to-severe-atopic-dermatitis-with-dupilumab-and/)
- [Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial](https://scholariq.org/papers/efficacy-and-safety-of-guselkumab-an-anti-interleukin-23-monoclonal-antibody/)
- [Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis](https://scholariq.org/papers/phase-3-trials-of-ixekizumab-in-moderate-to-severe-plaque-psoriasis/)
- [Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials](https://scholariq.org/papers/efficacy-and-safety-of-risankizumab-in-moderate-to-severe-plaque-psoriasis/)
- [Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*](https://scholariq.org/papers/tralokinumab-for-moderate-to-severe-atopic-dermatitis-results-from-two-52-week/)
- [The Role of AI, Machine Learning, and Big Data in Digital Twinning: A Systematic Literature Review, Challenges, and Opportunities](https://scholariq.org/papers/the-role-of-ai-machine-learning-and-big-data-in-digital-twinning-a-systematic/)
- [Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adults-with-moderate-to-severe-atopic/)
- [Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials](https://scholariq.org/papers/once-daily-upadacitinib-versus-placebo-in-adolescents-and-adults-with-moderate/)
- [Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials](https://scholariq.org/papers/tildrakizumab-versus-placebo-or-etanercept-for-chronic-plaque-psoriasis/)
- [Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis](https://scholariq.org/papers/risankizumab-versus-ustekinumab-for-moderate-to-severe-plaque-psoriasis/)
- [Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adolescents-with-uncontrolled-moderate-to/)

## University researchers

- [Syed Attique Shah](https://scholariq.org/researchers/syed-attique-shah/)

## University top topics

Showing 8 of 9.

- [Healthcare during COVID-19 Pandemic](https://scholariq.org/topics/healthcare-during-covid-19-pandemic/)
- [Music Education and Analysis](https://scholariq.org/topics/music-education-and-analysis/)
- [Health, Nursing, Elderly Care](https://scholariq.org/topics/health-nursing-elderly-care/)
- [Occupational Health and Burnout](https://scholariq.org/topics/occupational-health-and-burnout/)
- [Semiconductor materials and interfaces](https://scholariq.org/topics/semiconductor-materials-and-interfaces/)
- [Healthcare Regulation](https://scholariq.org/topics/healthcare-regulation/)
- [Semiconductor materials and devices](https://scholariq.org/topics/semiconductor-materials-and-devices/)
- [Youth, Drugs, and Violence](https://scholariq.org/topics/youth-drugs-and-violence/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.